Pharmacological management of Cronkhite-Canada syndrome

Eric M. Ward, Herbert C. Wolfsen

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome associated with characteristic ectodermal abnormalities. A number of potentially life-threatening complications including malnutrition, gastrointestinal bleeding and infection may occur in affected patients and CCS is fatal in many cases. The optimal therapy for CCS is not known but several treatment options have been described. Nutritional support, antibiotics, corticosteroids, anabolic steroids, histamine-receptor antagonists and surgical treatment have all been used with varying degrees of success. Unfortunately, controlled therapeutic trials have not been possible because of the rarity of the disease. Most recently, a combination regimen using histamine-receptor antagonists, cromolyn sodium, prednisone and suppressive antibiotics has been described. The reported treatment options and rates of success are reviewed.

Original languageEnglish (US)
Pages (from-to)385-389
Number of pages5
JournalExpert Opinion on Pharmacotherapy
Volume4
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Intestinal Polyposis
Pharmacology
Histamine Receptors
Histamine Antagonists
Testosterone Congeners
Anti-Bacterial Agents
Therapeutics
Cromolyn Sodium
Nutritional Support
Steroid Receptors
Prednisone
Malnutrition
Adrenal Cortex Hormones
Hemorrhage
Infection

Keywords

  • Corticosteroid
  • Cromolyn sodium
  • Cronkhite-Canada syndrome
  • Endoscopic therapy
  • Gastrointestinal polyposis syndromes
  • Idiopathic thrombocytopenic purpura
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacological management of Cronkhite-Canada syndrome. / Ward, Eric M.; Wolfsen, Herbert C.

In: Expert Opinion on Pharmacotherapy, Vol. 4, No. 3, 01.03.2003, p. 385-389.

Research output: Contribution to journalArticle

Ward, Eric M. ; Wolfsen, Herbert C. / Pharmacological management of Cronkhite-Canada syndrome. In: Expert Opinion on Pharmacotherapy. 2003 ; Vol. 4, No. 3. pp. 385-389.
@article{36dc545ff08d4b0097cd29fbb8280865,
title = "Pharmacological management of Cronkhite-Canada syndrome",
abstract = "Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome associated with characteristic ectodermal abnormalities. A number of potentially life-threatening complications including malnutrition, gastrointestinal bleeding and infection may occur in affected patients and CCS is fatal in many cases. The optimal therapy for CCS is not known but several treatment options have been described. Nutritional support, antibiotics, corticosteroids, anabolic steroids, histamine-receptor antagonists and surgical treatment have all been used with varying degrees of success. Unfortunately, controlled therapeutic trials have not been possible because of the rarity of the disease. Most recently, a combination regimen using histamine-receptor antagonists, cromolyn sodium, prednisone and suppressive antibiotics has been described. The reported treatment options and rates of success are reviewed.",
keywords = "Corticosteroid, Cromolyn sodium, Cronkhite-Canada syndrome, Endoscopic therapy, Gastrointestinal polyposis syndromes, Idiopathic thrombocytopenic purpura, Proton pump inhibitors",
author = "Ward, {Eric M.} and Wolfsen, {Herbert C.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1517/eoph.4.3.385.22239",
language = "English (US)",
volume = "4",
pages = "385--389",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Pharmacological management of Cronkhite-Canada syndrome

AU - Ward, Eric M.

AU - Wolfsen, Herbert C.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome associated with characteristic ectodermal abnormalities. A number of potentially life-threatening complications including malnutrition, gastrointestinal bleeding and infection may occur in affected patients and CCS is fatal in many cases. The optimal therapy for CCS is not known but several treatment options have been described. Nutritional support, antibiotics, corticosteroids, anabolic steroids, histamine-receptor antagonists and surgical treatment have all been used with varying degrees of success. Unfortunately, controlled therapeutic trials have not been possible because of the rarity of the disease. Most recently, a combination regimen using histamine-receptor antagonists, cromolyn sodium, prednisone and suppressive antibiotics has been described. The reported treatment options and rates of success are reviewed.

AB - Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome associated with characteristic ectodermal abnormalities. A number of potentially life-threatening complications including malnutrition, gastrointestinal bleeding and infection may occur in affected patients and CCS is fatal in many cases. The optimal therapy for CCS is not known but several treatment options have been described. Nutritional support, antibiotics, corticosteroids, anabolic steroids, histamine-receptor antagonists and surgical treatment have all been used with varying degrees of success. Unfortunately, controlled therapeutic trials have not been possible because of the rarity of the disease. Most recently, a combination regimen using histamine-receptor antagonists, cromolyn sodium, prednisone and suppressive antibiotics has been described. The reported treatment options and rates of success are reviewed.

KW - Corticosteroid

KW - Cromolyn sodium

KW - Cronkhite-Canada syndrome

KW - Endoscopic therapy

KW - Gastrointestinal polyposis syndromes

KW - Idiopathic thrombocytopenic purpura

KW - Proton pump inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0037348888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037348888&partnerID=8YFLogxK

U2 - 10.1517/eoph.4.3.385.22239

DO - 10.1517/eoph.4.3.385.22239

M3 - Article

C2 - 12614190

AN - SCOPUS:0037348888

VL - 4

SP - 385

EP - 389

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 3

ER -